The main findings of the trial were that:
a) High dose acid suppression significantly prevented progression to high grade dysplasia, cancer and especially all causes of mortality.
b) Aspirin also had an effect on these endpoints but only when patients who received non-steroidal anti-inflammatory drugs e.g. brufen were removed from the analysis prior to use.
c) The combination of high dose acid suppression and aspirin had a combinatorial effect i.e. worked better than either alone.
d) The safety of these agents over the 9 years was exceptional as <1% of patients had serious adverse events linked to the medications.
In summary we showed that taking high dose acid suppression significantly benefitted 1 in 34 patients in this way whereas aspirin benefitted 1 in 43 patients. This trial is also unique in that it looked at the combination of cancer prevention agents. The trial is now being assessed by the National Institute for Health and Care Excellence in the UK to see if National Guidelines need to change.
Please click here to read further details